All Insights Case Study Driving $25 Million Impact with a Data Science and Analytics Center of Excellence
Driving $25 Million Impact with a Data Science and Analytics Center of Excellence
Continuous innovation and streamlined operations are crucial in achieving positive patient outcomes. In the life sciences industry, data must be integrated seamlessly with advanced analytics to make timely, informed decisions. Without a centralized analytics practice, the risk of fragmented data management and operational inefficiencies grows, particularly in data cleaning, which hinders scalability and flexibility.
By establishing an Analytics Center of Excellence (CoE) specifically tailored to the unique needs of the pharmaceutical industry, business users can effectively centralize expertise, resources, and best practices to elevate enterprise analytics capabilities.
A leading biopharma company wanted to optimize its commercial analytics across multiple geographies. The company’s commercial analytics group recognized that it needed flexible and scalable data science capabilities to stay competitive. It wanted innovative solutions to enhance efficiency, reduce costs, and future-proof its data and analytics capabilities.
This case study illustrates Axtria’s collaboration with the biopharma company to establish a Data Science and Analytics CoE. Through this multi-year agreement, Axtria leveraged its extensive experience and best practices to enhance the biopharma company’s data science capabilities, drive significant business impact, and ensure sustainable growth. This case study describes the nuances of the newly formed COE.
In less than a year of operations, the CoE delivered an impact on multiple fronts:
- The biopharma company identified opportunities to increase revenue by ~$25 million across patient journeys, marketing mix, next best action, and predictive models.
- Generative AI-based intelligent bots achieved over 40% productivity gains.
- The orchestration engine for the biopharma’s flagship brand in the US significantly increased the brand’s new prescriptions.
- The biopharma realized significant cost savings through an offshore-heavy model, optimizing resource allocation and reducing overhead costs.
- Several other efficiency gains were observed.
Download this case study to learn more.
Contact us at connect@axtria.com with any questions.
Recommended insights
Report
Predictive Horizons: Unveiling Cardiovascular Insights with Conditional Inference Trees
Report